文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

重型再生障碍性贫血的替代供者移植:SAAWP EBMT的比较研究

Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT.
PubMed 文献 · Blood · 2024-01-01

该研究比较了欧洲血液与骨髓移植学会数据库中2012至2021年注册的1106例MUD、340例MMUD和206例Haplo移植的SAA患者结局。Haplo仅纳入移植后环磷酰胺预防GVHD者。MUD组急性GVHD、非复发死亡最低,总生存和GRFS最高;作者认为缺乏MSD时MUD为优选替代供者,MMUD与Haplo选择仍不确定,需进一步探索。

要点

  • 与MUD相比,MMUD(HR 2.93)和Haplo(HR 5.15)的原发性植入失败风险显著更高。
  • 3年总生存:MUD 81%、MMUD 74%、Haplo 63%(P < .001)。
  • 3年GRFS:MUD 73%、MMUD 65%、Haplo 54%(P < .001)。

核心结论

  • 对于缺乏MSD的SAA患者,作者认为研究结果支持MUD作为优选的替代供者选择。
  • 在MMUD与Haplo供者之间如何选择仍不确定,需要进一步探索。

研究设计与样本

  • 比较性研究,数据来自欧洲血液与骨髓移植学会数据库2012至2021年注册的SAA移植患者。
  • MUD组n = 1106,MMUD组n = 340,Haplo组n = 206。
  • Haplo移植仅纳入接受移植后环磷酰胺预防GVHD者。
  • 患者中位年龄20岁,诊断至移植中位时间8.7个月。

主要发现

  • 与MUD相比,MMUD(HR 2.93;95% CI 1.52-5.6)和Haplo(HR 5.15;95% CI 2.5-10.58)的原发性植入失败风险显著更高。
  • 急性GVHD 2-4级:MUD 13%、MMUD 22%、Haplo 19%(P < .001);3-4级:MUD 5%、MMUD 9%、Haplo 7%(P = .028)。
  • 3年非复发死亡率:MUD 14%、MMUD 19%、Haplo 27%(P < .001)。
  • 3年总生存率:MUD 81%、MMUD 74%、Haplo 63%(P < .001);3年GRFS率:MUD 73%、MMUD 65%、Haplo 54%(P < .001)。
  • 多变量分析除供者类型外,还与GRFS相关的因素包括患者年龄、体能状态和诊断至移植间隔。

临床怎么用

  • 对于缺乏MSD的SAA患者,作者认为研究结果支持MUD作为优选的替代供者选择。
  • 在MMUD与Haplo供者之间选择仍不确定,作者提出需要进一步探索。

局限性

  • 在MMUD与Haplo供者之间选择仍不确定,需要进一步探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Selecting the most suitable alternative donor becomes challenging in severe aplastic anemia (SAA) when a matched sibling donor (MSD) is unavailable. We compared outcomes in patients with SAA undergoing stem cell transplantation (SCT) from matched unrelated donors (MUD) (n = 1106), mismatched unrelated donors (MMUD) (n = 340), and haploidentical donors (Haplo) (n = 206) registered in the European Society for Blood and Marrow Transplantation database (2012-2021). For Haplo SCT, only those receiving posttransplant cyclophosphamide for graft-versus-host disease (GVHD) prophylaxis were included. Median age was 20 years, and the median time from diagnosis to transplantation 8.7 months. Compared with MUD, MMUD (hazard ratio [HR], 2.93; 95% confidence interval [CI], 1.52-5.6) and Haplo (HR, 5.15; 95% CI, 2.5-10.58) showed significantly higher risks of primary graft failure. MUD had lower rates of acute GVHD compared with MMUD and Haplo (grade 2-4: 13%, 22%, and 19%, respectively; P < .001; grade 3-4: 5%, 9%, and 7%, respectively; P = .028). The 3-year nonrelapse mortality rate was 14% for MUD, 19% for MMUD, and 27% for Haplo (P < .001), whereas overall survival and GVHD and relapse-free survival (GRFS) rates were 81% and 73% for MUD, 74% and 65% for MMUD, and 63% and 54% for Haplo, respectively (P < .001). In addition to donor type, multivariable analysis identified other factors associated with GRFS such as patient age, performance status, and interval between diagnosis and transplantation. For patients with SAA lacking an MSD, our findings support MUDs as the preferable alternative donor option. However, selecting between an MMUD and Haplo donor remains uncertain and requires further exploration.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Montoro J, Eikema DJ, Tuffnell J, et al. Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT. Blood. 2024. PMID: 38643511. doi:10.1182/blood.2024024173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。